U.S. flag An official website of the United States government
  1. Home
  2. News & Events
  3. FDA Meetings, Conferences and Workshops
  4. Public meeting: FDA Rare Disease Day 2024 - 03/01/2024
  1. FDA Meetings, Conferences and Workshops

Virtual | Virtual

Event Title
Public meeting: FDA Rare Disease Day 2024
March 1, 2024


Date:
March 1, 2024
Time:
9:00 AM - 4:30 PM ET
Organized By:
Image
FDA's Rare Disease Day 2024 Virtual Public Meeting. March 1, 2024. Dedicated to patients and providers. Register today!

Meeting recording

Watch the full meeting recording or for specific panels, please visit:

Summary

FDA will host Rare Disease Day, a virtual public meeting, on March 1, 2024 in global observance of Rare Disease Week. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss: 

  • The legal framework for approving studies and medical products at FDA 
  • What FDA does during review processes to approve medical products 
  • Decentralized clinical trials and digital health technologies 
  • Where to find important information and documents related to clinical trials 
  • Information that can be obtained from medical product labels 
  • Legal and ethical requirements for consent forms in clinical trials 
  • FDA initiatives to advance medical product development for rare diseases 
  • Ways for patients to engage with FDA 

Agenda and materials

View the agenda (PDF, 2.39 MB) for detailed information about this event, including speaker bios. Where available, slides from each speaker are provided below, under Event Materials.

Continuing education credit

Free continuing education (CE) credit is available for physicians, physician assistants, pharmacists, pharmacy technicians, nurses, and certified public health professionals who attend FDA’s Rare Disease Day. This event is approved for 4.25 CE credit hours. See the Activity Outline and CE credit claiming instructions (PDF, 436.98 KB) for more information.

Public docket

Stakeholders are invited to provide their perspectives on the discussion questions through the public docket. All comments must be identified with the docket number FDA-2023-N-5211 through April 5, 2024. 

Contact

Participants may submit questions in advance to OOPDOrphanEvents@fda.hhs.gov

Office of Clinical Policy and Programs, Office of Orphan Products Development | 301-796-7634 


 
Back to Top